IIR Austria Spital 2016 – Wien

MH News

IIR Austria Spital 2016 – Wien

Mit einem Vortrag zur „Evidenzbasierten molekularen Dateninterpretation in der personalisierten Tumortherapie“ von Dr. Sandra Morandell präsentierte sich Molecular Health auf der diesjährigen IIR Spital 2016 in Vösendorf bei Wien und stieß auf großes Interesse bei den 250 Teilnehmern und den Gesprächspartnern der österreichischen onkologischen Community.

Other Articles

In der Ausgabe Management & Krankenhaus 9/2016 äußerts Geschäftsführer von Molecular Health, Dr. Stephan Brock  interviewt.

Monday, October 24th

apotheke adhoc schreibt über Molecular Health und neue Diagnoseverfahren:

Die Krebstherapie steht nach Einschätzung von Wissenschaftlern, Ärzten und Herstellern in den kommenden Jahren vor einer Revolution. Neue Diagnoseverfahren und darauf basierende Therapien versprechen einen Durchbruch, der sogar die Heilung von Krebs zur Realität oder den Krebs zumindest zu einer beherrschbaren Volkskrankheit machen könnte. Gentechnik und Big Data spielen dabei die entscheidende Rolle

Monday, September 19th

Gerry Sheridan zum Chief Financial Officer und Dr. Les Paul zum Chief Medical Officer ernannt

Monday, August 15th

Bundesforschungsministerin Johanna Wanka hat am 16. November 2015 auf der internationalen Messe MEDICA das neue Förderkonzept „Medizininformatik“ erstmals einer breiten Fachöffentlichkeit vorgestellt. Ziel des Förderkonzepts ist es, die Patientenversorgung und die Forschungsmöglichkeiten durch innovative IT-Systeme zu verbessern. Diese IT-Systeme sollen die Nutzung von Daten aus Krankenversorgung, biomedizinischer und klinischer Forschung über die Grenzen von Institutionen und Standorten hinweg ermöglichen.
 

Friday, July 29th

Auf Einladung des Bayerischen Staatsministeriums für Wirtschaft und Medien, Energie und Technologie hat Friedrich von Bohlen, CEO von Molecular Health, am 30.06.2016 einen Impulsvortrag zum Thema „Precision Medicine“ im Rahmen der Veranstaltung „Digitalisierung der Medizin in Bayern – Fokus klinische Patientendaten“ gegeben.
 
Es waren hochrangige Vertreter aus Klinik, Forschung, Politik und Wirtschaft anwesend, um praktische Herausforderungen und notwendige Maßnahmen zu diskutieren und formulieren, um die Digitalisierung der Medizin in Bayern voranzutreiben.

Friday, July 29th

Molecular Health war mit einem Fachexperten als Referent zu Gast bei der Podiumsdiskussion des diesjährigen ApoForums „Digital Health – Disruption oder Evolution der Gesundheitsversorgung?“ am 29. Juni in Düsseldorf. Dr. Mathias Göschl (Vice President, Content) diskutierte mit Führungskräften der Gesundheitsbranche, Ärzten, Apothekern und Experten aus Politik und Wissenschaft.

Friday, July 29th

Molecular Health will no longer provide its end-to-end cancer diagnostic medical services in the US and thus will terminate processing patient cases effective August 19, 2016. In order to honor our turn-around time commitments, we will not be accepting any new patient cases after July 29, 2016.

 

In the future, Molecular Health will be focusing its efforts to further develop its information solutions for clinical decision support in oncology and drug safety, MH Guide and MH Effect, and its Dataome technology platform.

 

Wednesday, July 27th

Appoints Gerry Sheridan as Chief Financial Officer

 

Appoints Dr. Les Paul as Chief Medical Officer

 

Friday, July 22nd

Results published today in Cancer Cell validate new diagnostic biomarker for reducing adverse events and improving outcomes of cancer patients with anemia

Findings enable potential patient stratification for tailored treatment

Friday, June 17th

Enrollment Now Open for Early Access Program (EAP) Set to Launch in November 2015

Cambridge, MA – October 5, 2015 – Molecular Health, a leader in cloud-based healthcare decision support technology to optimize the selection of therapies for improved patient outcomes, today announced that it will initiate an early access program (EAP) offering its SafetyMAP™ software to pharmaceutical companies and clinical professionals involved in drug safety starting in November 2015.

Friday, June 17th

The "Corporate Oncology Program for Employees" with Molecular Health

Schwalbach/Heidelberg - September 23, 2015 - As of September 1, 2015, EMC in Germany will be joining forces with Molecular Health to launch a Corporate Oncology Program for Employees (COPE). If an EMC employee or the spouse, partner, or child of an EMC employee are diagnosed with cancer, the program will fund an analysis of the patient's tumor genome so that the most promising treatment options can be identified.

Friday, June 17th

Cambridge, MA – September 9, 2015 – Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP™ software - formerly known as Molecular Analysis of Side Effect information (MASE™), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.

Friday, June 17th

Germline biomarkers predicted drug toxicity: impact on clinical routine

June 30, 2015, Heidelberg/Cambridge, MA. A core tenet of precision medicine is that predictive biomarkers can enhance therapeutic decision-making. In a new pilot study, scientists at Molecular Health analyzed a randomly selected set of 250 patients with solid tumors and detected predictive biomarkers in more than 85% of tumors.

Friday, June 17th

Many tests for predictive biomarkers in tumors focus on selected known mutations

June 29, 2015. Heidelberg / Cambridge, MA. Many tests for predictive biomarkers in tumors focus on selected known mutations or regions (e.g., hotspot panels). In a new study, scientists at Molecular Health examined the rates of secondary mutations in known biomarker genes and their potential impact on the diagnostic reliability of specific single-nucleotide variant (SNV) biomarker testing.

Friday, June 17th

June 4, 2015

Cambridge, MA, Houston, TX – Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting.  TestAnalytika will begin to market and distribute Molecular Health’s cancer treatment decision support product, TreatmentMAP™, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

Friday, June 17th

The Guardian Research Network and Molecular Health will Provide Cancer Patients with Personalized Clinical Decision Support

CAMBRIDGE, Massachusetts and SPARTANBURG, South Carolina, May 29, 2015

The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

Friday, June 17th

Category at SAPPHIRE® NOW Conference

May 8, 2015 Cambridge, MA / Heidelberg, Germany - Molecular Health today announced it has won an SAP HANA® Innovation Award in the category Technology Trailblazer - Business Application. The awards presented by SAP SE (NYSE: SAP) recognize the extraordinary ways that customers are using the SAP HANA platform to transform their business and society. 

Molecular Health received its award at a ceremony hosted by SAP at SAPPHIRE® NOW and the ASUG Annual Conference held May 5-7 in Orlando, Fla.

Friday, June 17th

Addresses unmet need in treatment of millions of cancer patients

April 27, 2015 Cambridge, MA / Heidelberg, Germany -- Molecular Health announced today it has been granted a patent in Europe entitled “Tissue Protective Erythropoietin Receptor”. This latest patent supports Molecular Health’s discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth. 

Friday, June 17th
  • GATC Biotech to play an essential role in the commercialisation of TreatmentMAP™
  • Significantly increased access to the first registered medical device for personalised cancer medicine in Europe
  • GATC Biotech expands the market reach and opportunities of its Diagnostic Solutions division

Constance, Germany, 21 April 2015: GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, announced today that it has signed a commercial agreement with Molecular Health.

Friday, June 17th

HEIDELBERG, Germany & THE WOODLANDS, Texas--(BUSINESS WIRE)--Molecular Health announced today that its chief innovation officer, David Jackson, Ph.D., will speak at this year’s 

Friday, June 17th